Hawaii Business Magazine

Hawaii Biotech is a clinical-stage biotechnology company based in Hawaii, specializing in the development of recombinant protein vaccines and small molecule therapeutics for infectious diseases and biodefense. The company's pipeline includes vaccine candidates for West Nile virus, Zika virus, Chikungunya, and various viral hemorrhagic fevers, as well as anti-toxin drugs for Anthrax and Botulism. Hawaii Biotech utilizes a proprietary insect cell-based protein production platform to create highly immunogenic antigens that mimic native viral structures. The company has a history of successful partnerships, including the out-licensing of its Dengue vaccine candidate to Merck, and receives significant funding from the NIH and Department of Defense.